Project will use big data and analytics to address pressing public health issue
Bettis unveils new playbook for defending against severe allergic reactions and affected to take action
First patient enrolled in Phase III clinical trial for moxetumomab pasudotox as a treatment for unresponsive or relapsed hairy cell leukemia patients
Simponi has already been approved by the FDA for the treatment of moderately to severely active rheumatoid arthritis
Like a game of whack-a-mole, no matter how many times Johnson & Johnson attempts to put to rest lawsuits over the marketing of its Risperdal...
Heinz-Werner Meier, who runs the drugmaker's German operations, will leave his post at the end of the year,Financial Times Deutschland reported.
Meier, a long-time executive at German drugs and chemicals maker Hoechst, which is now part of Sanofi-Aventis, will also resign from his role as the worldwide head of human resources on September 1. Meier informed staff of his decision in a letter, which was obtained by Financial Times Deutschland, the paper said.
Hat tip to Pharmagossip
